Trial of Filgrastim Versus Placebo Following Allogeneic Bone Marrow Transplantation
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00207792|
Recruitment Status : Unknown
Verified September 2007 by Centre National de Greffe de Moelle Osseuse.
Recruitment status was: Recruiting
First Posted : September 21, 2005
Last Update Posted : November 6, 2007
The effect of haematopoietic growth factors on neutrophil recovery after allogeneic bone marrow transplantation is well recognized. Recent laboratory studies demonstrated that these cytokines may also modify T-cell and dendritic cell function, but whether the effect is strong enough to alter the risk of graft-versus-host disease (GvHD) is unclear.
The aim of this randomised study is to determine the effect of granulocyte colony-stimulating factor [G-CSF] (Neupogen; filgrastim) on the risk of acute GvHD after allogeneic bone marrow transplantation.
|Condition or disease||Intervention/treatment||Phase|
|Graft vs Host Disease||Drug: filgrastim||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||160 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Randomized Trial of Filgrastim Versus Placebo Following Allogeneic Bone Marrow Transplantation|
|Study Start Date :||July 2005|
U.S. FDA Resources
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00207792
|Contact: Tarek Ben Othman, MD||98901456 ext firstname.lastname@example.org|
|Centre National de Greffe de Moelle Osseuse||Recruiting|
|Contact: Tarek Ben Othman, MD 98901456 ext 00216 email@example.com|
|Principal Investigator: Tarek Ben Othman, MD|
|Principal Investigator:||Tarek Ben Othman, MD||Centre National de Greffe de Moelle Osseuse|